Cell line name |
HCT-116/SN-38 |
Accession |
CVCL_WV82 |
Resource Identification Initiative |
To cite this cell line use: HCT-116/SN-38 (RRID:CVCL_WV82) |
Comments |
Population: Caucasian. Doubling time: 29 hours (PubMed=23546019). Selected for resistance to: ChEBI; CHEBI_8988; SN-38 (7-ethyl-10-hydroxy-camptothecin). Derived from site: In situ; Colon; UBERON=UBERON_0001155. |
Sequence variations |
- Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
|
Disease |
Colon carcinoma (NCIt: C4910) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0291 (HCT 116) |
Sex of cell |
Male |
Age at sampling |
48Y |
Category |
Cancer cell line |
Publications | PubMed=23546019; DOI=10.3892/ijo.2013.1868 Petitprez A., Poindessous V., Ouaret D., Regairaz M., Bastian G., Guerin E., Escargueil A.E., Larsen A.K. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status. Int. J. Oncol. 42:1644-1653(2013) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_WV82
|
Encyclopedic resources |
Wikidata; Q93985421
|
Entry history |
Entry creation | 05-Jul-2019 |
Last entry update | 19-Dec-2024 |
Version number | 9 |
---|